Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Source:http://linkedlifedata.com/resource/pubmed/id/16585503

Proc. Natl. Acad. Sci. U.S.A. 2006 Apr 11 103 15 5941-6

Download in:

View as

Triples

General Info

PMID
16585503